Global Migraine Therapeutics Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Drug Class;

Triptans - Maxalt (Rizatriptan Benzoate), Rizaport (Rizatriptan Benzoate), Sumavel DosePro (Sumatriptan Succinate), Treximet (Sumatriptan Succinate and Sodium Naproxen), Relpax (Eletriptan Hydrobromide), Onzetra Xsail (Sumatriptan Succinate) and Others, Calcitonin Gene-Related Peptide (CGRP).Inhibitors - Aimovig (Erenumab), Ajovy (Fremanezumab-vfrm) and Emgality (Galcanezumab-gnlm), Botulinum Toxin, Antidepressants, Anti-epileptics and Others.

By Disease Indication;

Episodic Migraine and Chronic Migraine.

By Distribution Channel;

Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies.

By Geography;

North America, Europe, Asia Pacific, Middle East Africa, and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn934678908 Published Date: January, 2025 Updated Date: February, 2025

Introduction

Global Migraine Therapeutics Market (USD Million), 2021 - 2031

In the year 2024, the Global Migraine Therapeutics Market was valued at USD 1,304.51 million. The size of this market is expected to increase to USD 2,024.54 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 6.5%.

The global migraine therapeutics market is witnessing significant growth, driven by various factors such as the rising prevalence of migraine disorders, advancements in treatment options, and increasing awareness among both healthcare professionals and patients. Migraine is a debilitating neurological disorder characterized by recurrent severe headaches, often accompanied by other symptoms like nausea, vomiting, and sensitivity to light and sound. With millions of individuals worldwide affected by migraines, there's a pressing need for effective therapeutic interventions to alleviate symptoms and improve patients' quality of life.

Over the years, the pharmaceutical industry has made strides in developing innovative migraine treatments, including both acute and preventive medications. These include triptans, nonsteroidal anti-inflammatory drugs (NSAIDs), antiemetics, and recently, calcitonin gene-related peptide (CGRP) monoclonal antibodies, which have emerged as a promising class of drugs specifically designed for migraine prevention. The availability of a diverse range of treatment options allows healthcare providers to tailor therapies according to individual patient needs, contributing to the overall growth of the migraine therapeutics market.

Increasing research and development activities focused on understanding the underlying mechanisms of migraines and identifying novel therapeutic targets are further propelling market expansion. Collaborations between pharmaceutical companies, academic institutions, and research organizations are facilitating the discovery of new drug candidates and the development of more targeted and efficacious treatments. Additionally, the growing adoption of telemedicine and digital health solutions is improving access to migraine care, particularly in underserved regions, thereby widening the market scope.

Despite these advancements, several challenges persist, such as the high cost of novel migraine therapies, the presence of generic alternatives, and the underdiagnosis of migraines in certain populations. Addressing these challenges requires concerted efforts from stakeholders across the healthcare ecosystem to ensure affordable access to treatment, enhance disease awareness and education, and improve healthcare infrastructure. Overall, with ongoing innovation and a growing understanding of migraine pathophysiology, the global migraine therapeutics market is poised for continued growth in the coming years.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Drug Class
    2. Market Snapshot, By Disease Indication
    3. Market Snapshot, By Distribution Channel
    4. Market Snapshot, By Region
  4. Global Migraine Therapeutics Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Increasing migraine prevalence
        2. Advances in treatment options
        3. Growing awareness campaigns
        4. Rising healthcare expenditure
        5. Technological innovations support
      2. Restraints
        1. Side effects concerns
        2. Regulatory hurdles
        3. Generic competition pressures
        4. Limited efficacy in some
        5. High treatment costs
      3. Opportunities
        1. Emerging markets expansion
        2. Personalized medicine approaches
        3. Novel drug development
        4. Telemedicine adoption rises
        5. Collaborative research initiative
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitve Rivalry
  5. Market Segmentation
    1. Global Migraine Therapeutics Market, By Drug Class, 2021 - 2031 (USD Million)
      1. Triptans
      2. Maxalt (Rizatriptan Benzoate)
      3. Rizaport (Rizatriptan Benzoate)
      4. Sumavel DosePro (Sumatriptan Succinate)
      5. Treximet (Sumatriptan Succinate and Sodium Naproxen)
      6. Relpax (Eletriptan Hydrobromide)
      7. Onzetra Xsail (Sumatriptan Succinate)
      8. Others
      9. Calcitonin Gene-Related Peptide (CGRP) Inhibitors
        1. Aimovig (Erenumab)
        2. Ajovy (Fremanezumab-vfrm)
        3. Emgality (Galcanezumab-gnlm)
      10. Botulinum Toxin
      11. Antidepressants
      12. Anti-epileptics
      13. Others
    2. Global Migraine Therapeutics Market, By Disease Indication, 2021 - 2031 (USD Million)
      1. Episodic Migraine
      2. Chronic Migraine
    3. Global Migraine Therapeutics Market, By Distribution Channel, 2021 - 2031 (USD Million)
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
    4. Global Migraine Therapeutics Market, By Geography,2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Allergan Plc.
      2. Ironwood Pharmaceuticals, Inc
      3. Astellas Pharma Inc.
      4. Takeda Pharmaceutical Company Ltd
      5. Mallinckrodt Plc (Sucampo Pharmaceuticals)
      6. AstraZeneca Plc
      7. Sebela Pharmaceuticals Inc.
      8. GlaxoSmithKline Plc
      9. Synergy Pharmaceuticals Inc.
      10. Ardelyx, Inc.
      11. Synthetic Biologics, Inc.
      12. Napo Pharmaceuticals, Inc.
      13. Axim Biotechnologies, Inc.
      14. Salix Pharmaceuticals, Inc
  7. Analyst Views
  8. Future Outlook of the Market